Hospital & Healthcare Management August 10, 2024
The National Health Service (NHS) patients who are now afflicted with a hereditary blood condition are going to be among the first people in the world to get the “life-changing” gene-editing procedure that offers the possibility of a cure.
The National Institute for Health and Care Excellence (NICE) has given its approval for the use of the one-off gene therapy known as Casgevy on the National Health Service (NHS) in England, beginning on August 8th. This approval is for older children and adults who have a severe type of thalassaemia treatment.
There are around 460 individuals in England who are presently living with transfusion-dependent beta thalassaemia and are at least 12 years old. These patients may be eligible for the...
Today's Sponsors
Today's Sponsor